As a vascular endothelial growth factor (VEGF) antibody, bevacizumab not only alleviates HHT-related hepatic AVMs and high-output heart failure but may also serve as a therapeutic option for recurrent HCC (13). Here, VEGFA is linked to hepatocellular carcinoma.